Adoptive Cell Therapy (ACT) is a novel approach to cancer treatment, which implements the use of the patient T-cells redirected to eradicate tumour cells. The T-cells are engineered to express a Chimeric Antigen Receptor (CAR) that bestows specificity for an arbitrary antigen. CAR-T cell clinical trials have shown tumour eradication of leukaemia, but modest results against solid tumours. There is an ongoing debate regarding the correlation of CAR affinity and antigen-density recognition threshold, which we sought to investigate. Although the TCRs sensitivity against low antigen targets is superior at low-affinity, the effect of affinity in CAR efficacy and sensitivity is controversial. In order to examine the correlation between CAR efficac...
© 2014 Dr. Connie DuongAdoptive immunotherapy is a promising treatment for cancer, with response rat...
Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the therapeuti...
2019-04-19Adoptive transfer of chimeric antigen receptor (CAR) engineered T cells is an emerging can...
Adoptive T cell therapies have achieved significant clinical responses, especially in hematopoietic ...
Insufficient reactivity against cells with low antigen density has emerged as an important cause of ...
The effectiveness of chimeric Ag receptor (CAR)-transduced T (CAR-T) cells has been attributed to su...
© 2016 Dr Alexander DavenportDespite the success of autologous chimeric antigen receptor (CAR) T cel...
Chimeric antigen receptor (CAR) T-cell therapy has been successful in treating liquid tumors but has...
Background: T cells expressing chimeric antigen receptors (CARs) have shown exciting promise in canc...
Purpose: Targeting nonspecific, tumor-associated antigens (TAA) with chimeric antigen receptors (CAR...
Chimeric Antigen Receptor T cell (CAR-T) therapy has shown remarkable success in the treatment of he...
BackgroundT cells expressing chimeric antigen receptors (CARs) have shown exciting promise in cancer...
Chimeric antigen receptor (CAR) T-cell therapy has been widely successful in the treatment of B-cell...
Chimeric antigen receptor (CAR) T cells are “living drugs” that specifically recognize their target...
Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune responses. Tum...
© 2014 Dr. Connie DuongAdoptive immunotherapy is a promising treatment for cancer, with response rat...
Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the therapeuti...
2019-04-19Adoptive transfer of chimeric antigen receptor (CAR) engineered T cells is an emerging can...
Adoptive T cell therapies have achieved significant clinical responses, especially in hematopoietic ...
Insufficient reactivity against cells with low antigen density has emerged as an important cause of ...
The effectiveness of chimeric Ag receptor (CAR)-transduced T (CAR-T) cells has been attributed to su...
© 2016 Dr Alexander DavenportDespite the success of autologous chimeric antigen receptor (CAR) T cel...
Chimeric antigen receptor (CAR) T-cell therapy has been successful in treating liquid tumors but has...
Background: T cells expressing chimeric antigen receptors (CARs) have shown exciting promise in canc...
Purpose: Targeting nonspecific, tumor-associated antigens (TAA) with chimeric antigen receptors (CAR...
Chimeric Antigen Receptor T cell (CAR-T) therapy has shown remarkable success in the treatment of he...
BackgroundT cells expressing chimeric antigen receptors (CARs) have shown exciting promise in cancer...
Chimeric antigen receptor (CAR) T-cell therapy has been widely successful in the treatment of B-cell...
Chimeric antigen receptor (CAR) T cells are “living drugs” that specifically recognize their target...
Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune responses. Tum...
© 2014 Dr. Connie DuongAdoptive immunotherapy is a promising treatment for cancer, with response rat...
Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the therapeuti...
2019-04-19Adoptive transfer of chimeric antigen receptor (CAR) engineered T cells is an emerging can...